Philips-sponsored study shows great promise for improving quality of life for millions of patients suffering from COPD


Preliminary study results released at European Respiratory Society (ERS) International Congress 2016 reveal reduced readmissions with use of home non-invasive ventilation

September 6, 2016

London, UK and Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced preliminary results of an independent, multi-center Home Oxygen Therapy – Home Mechanical Ventilation (HOT-HMV) study carried out by respiratory experts at St Thomas’ Hospital in London. Philips’ pioneering work in chronic obstructive pulmonary disease (COPD) started several decades ago when it began providing healthcare professionals and patients with innovative treatment solutions and services. Philips’ participation in the HOT-HMV study builds on the company’s global leadership in COPD management.

 

COPD is on the rise worldwide, estimated to become the third leading cause of death in the next fifteen years, more than breast cancer, colorectal cancer and prostate cancer combined1. Moreover, the U.S. Center for Disease Control and Prevention (CDC) estimates that caring for patients with these chronic conditions, including COPD, accounts for 70 percent of the annual healthcare spending in the United States alone2.

 

The Philips-sponsored study researched the benefits of home non-invasive ventilation (NIV), referred to as HMV in the study, for patients with COPD. Initial results from this study, which will be presented today at the European Respiratory Society (ERS) International Congress, reveal that patients using HOT with HMV are half as likely to be readmitted to the hospital. The HOT-HMV study used a randomized controlled trial that compared the use of HMV and HOT therapies with HOT alone in 116 patients with persistent hypercapnia. Investigators included Dr. Nicholas Hart, Dr. Patrick Murphy and colleagues.

 

“Our goal with this study was to find a way to provide COPD patients with oxygen therapy, as well as home ventilators,  in an effort to lower the number of patients being readmitted to hospitals,” said Dr. Nicholas Hart, professor and clinical and academic director of Lane Fox Respiratory Unit, St Thomas' Hospital. “The results of the HOT-HMV study have the ability to change the way that COPD patients are treated worldwide. We’re looking forward to continuing the trial over the next five years to monitor survival rates, which we hope will rise, and readmission rates, which will hopefully fall.”

 

“Philips is proud to be a lead sponsor of this study,” said Eli Diacopoulos, Business Leader, Home Respiratory Care, Philips. “Managing COPD is more than simply providing patients with respiratory devices, which is why Philips continues to innovate and advance NIV therapies in the hospital and home. It’s about providing support across the entire continuum of care, and Philips is uniquely positioned to make this a reality.”

 

In 2015, Philips funded and co-authored a retrospective study that evaluated COPD patients who were hospitalized two or more times within a year and transitioned to a COPD management program. The results of the study showed that the readmission rate on patients using NIV therapy in combination with a multifaceted program of clinical support services was reduced by 88 percent during the subsequent 12 months3.

 

Philips actively strives to help COPD patients in the home by connecting the company’s broad respiratory care portfolio – drug delivery, oxygen therapy, telehealth and home ventilation. The company continues to innovate and advance NIV therapies in the hospital and home with its advanced therapy algorithms for COPD and other chronic respiratory disorders.

 

To experience the entire portfolio of sleep and respiratory products, visit Philips at booth B-07 at the European Respiratory Society (ERS) International Congress 2016 in London (September 3-7).  For updates on Philips’ presence at ERS 2016, visit http://philips.to/2b2GIEr. For more information on Philips’ advanced solutions for sleep and respiratory care and updates from the show, visit @PhilipsResp and follow #breatheinlife.

 

[1] World Health Organization. 2008. Retrieved from http://www.who.int/respiratory/copd/World_Health_ Statistics_2008/en/

[2]  Center for Disease Control. 2009. Retrieved from www.cdc.gov/chronicdisease/pdf/2009-power-of-prevention.pdf

[3] Journal of Clinical Sleep Medicine. 2015. Retrospective Assessment of Home Ventilation to Reduce Rehospitalization in Chronic Obstructive Pulmonary Disease. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442227/

For further information, please contact:

Alicia Cafardi

Philips Group Communications

alicia.cafardi@philips.com

412-523-9616

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company, headquartered in the Netherlands, is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Philips Respironics

Philips Respironics is a global leader in the sleep and respiratory care markets, offering solutions in sleep apnea management, oxygen therapy, noninvasive ventilation and respiratory drug delivery. With more than 10 years of cloud-based data sharing experience and analytics for more than 7 million patient lives, Philips Respironics has a long history of leading new innovation in both devices and informatics solutions to help patients sleep and breathe better.